Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC001 plus paclitaxel versus placebo plus paclitaxel for previously treated advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2300071906Phase 3Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BC001 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Overall survival. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
BC001
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300071906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071906.